Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women who are at least 18 years old
• People who are willing and able to follow the study requirements and have signed a consent form
• People who have been diagnosed (confirmed by laboratory testing of tissue) with recurrent or persistent clear cell carcinoma of the ovary, endometrium, cervix, vagina, or vulva — with local review by a specialist pathologist required, and at least 50% clear cell type if the cancer is a mixed type
• People whose cancer has come back or gotten worse within 12 months of finishing platinum-based chemotherapy
• People who have received between 1 and 5 previous treatment courses for their cancer
• People whose cancer can be measured on scans using standard criteria (RECIST 1.1)
• People who are generally well enough to carry out light activity and care for themselves (rated 0 or 1 on a standard health scale used in cancer trials)
• People who have stored tumour tissue available, or can provide at least 20 tissue slides, for research purposes
• People who agree to have a fresh tumour biopsy taken, where at least one tumour can be safely accessed for this purpose (confirm with trial site)
• People whose blood, kidney, and liver function results fall within acceptable ranges as determined by the trial team
• People who have a negative pregnancy test within 72 hours before starting the study drug, unless they are confirmed to be unable to become pregnant (for example, due to menopause, surgical removal of the uterus or ovaries, or tubal ligation — confirmed by medical records)
• People who are able to become pregnant and agree to use a highly effective method of contraception from the time of consent until 180 days after the last dose of study treatment

Who may not be able to join:

• People who have had 6 or more previous courses of chemotherapy
• People who have previously received certain types of immunotherapy drugs that work on the PD-1 or PD-L1/PD-L2 pathways
• People who have received chemotherapy, targeted therapy, hormone therapy, or radiotherapy within the past 21 days (or within a shorter window based on the specific drug used)
• People who have a medical reason that makes chemotherapy, immunotherapy, or anti-blood vessel growth treatments unsafe for them
• People with persistently high blood pressure that has not been brought under control (confirmed over multiple readings across at least two separate appointments)
• People with significant uncontrolled bleeding or blood clotting problems (not related to blood-thinning medication)
• People who currently have a fistula (an abnormal opening or tunnel) in the abdomen or pelvis
• People who have another current cancer, or a previous non-gynaecological cancer that has not been fully clear for at least 3 years or that was actively treated in the last 3 years (non-melanoma skin cancer is generally allowed)
• People with active, uncontrolled cancer spread to the brain or the lining around the brain (note: previously treated and stable brain metastases may be considered — confirm with trial site)
• People with a known history of HIV, unless specific conditions are met regarding immune cell counts, viral load, medication, and absence of certain HIV-related illnesses (confirm with trial site)
• People with active hepatitis B or a positive hepatitis C antibody test at the time of screening, unless specific conditions relating to viral levels or completed treatment are met (confirm with trial site)
• People with an active autoimmune disease that required systemic (whole-body) medical treatment within the past 2 years (hormone replacement, such as thyroid medication or insulin, is not considered in this category)
• People with a known immune deficiency condition, or who have received immune-suppressing medications within 7 days before the first dose (some low-dose or one-time exceptions may apply after discussion with the trial team)
• People who have not yet recovered from side effects of previous cancer treatments (side effects must generally be at a mild level or lower, with some exceptions such as mild nerve symptoms, hair loss, or fatigue)
• People who have not fully recovered from a major surgical procedure, or who have had major surgery within 4 weeks before starting the study
• People with a known allergy to bevacizumab or dostarlimab, or to any of their ingredients
• People who are currently in another clinical trial or have received an experimental treatment within 4 weeks of the first study dose
• People with serious uncontrolled medical conditions, such as active lung inflammation, recent heart attack (within 90 days), uncontrolled seizures, severe infection requiring treatment, or serious psychiatric or substance use conditions
• People with a known history of non-infectious lung inflammation that required steroid treatment, or who currently have lung inflammation
• People who have received certain immune-boosting treatments (such as interferons, interleukins, or live vaccines) within 28 days before the first study dose
• People who are currently pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study period and for 180 days after the last dose

Important: Always verify eligibility with the trial site directly before applying.